title: HDAC inhibitors: double edge sword for TRAIL cancer therapy?
authors.affiliation: University Children's Hospital, Ulm, Germany. simone.fulda@medizin.uni-ulm.de
authors.forename: Simone
authors.initials: S
authors.lastname: Fulda
authors.forename: Klaus-Michael
authors.initials: KM
authors.lastname: Debatin
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D051017:Apoptosis Regulatory Proteins / Q000235:genetics / Q000494:pharmacology*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D008562:Membrane Glycoproteins / Q000235:genetics / Q000494:pharmacology*; D009369:Neoplasms / Q000145:classification / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D053221:TNF-Related Apoptosis-Inducing Ligand; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics / Q000494:pharmacology*
chemical_list: D051017:Apoptosis Regulatory Proteins; D004791:Enzyme Inhibitors; D056572:Histone Deacetylase Inhibitors; D008562:Membrane Glycoproteins; D053221:TNF-Related Apoptosis-Inducing Ligand; C505653:TNFSF10 protein, human; D014409:Tumor Necrosis Factor-alpha